top of page
  • Recruiting
    • Dec 27, 2020

NCT04674813: Phase 1 - A Study of CC-95266 in Subjects With Relapsed and/or Refractory Myeloma

Updated: Sep 2, 2022

A Study of CC-95266 in Subjects With Relapsed and/or Refractory Multiple Myeloma

CC-95266

This is a Phase 1, multicenter, open label, study of CC-95266 in subjects with relapsed and/or refractory multiple myeloma. The study will consist of two parts: dose escalation (Part A) and dose expansion (Part B). The dose escalation (Part A) of the study will evaluate the safety and tolerability of increasing doses of CC-95266 in a single administration to establish a maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D), and the dose expansion (Part B) of the study will further evaluate the safety, pharmacokinetics (PK)/ pharmacodynamics (PD), and efficacy of CC-95266 at the RP2D.


Sponsor

Juno Therapeutics, a Subsidiary of Celgene


Multiple Locations

 

ClinicalTrials.gov Identifier: NCT04674813


Official Title: A Phase 1, Multicenter, Open-Label Study of CC-95266 in Subjects With Relapsed and/or Refractory Multiple Myeloma


First Posted : December 19, 2020


Click here for details on ClinicalTrials.gov